...kinase receptor 1 ( TrkA ; NTRK1) inhibitor. Sienna said it also plans to develop SNA-125...

...completed Phase II trials to treat psoriasis vulgaris and atopic dermatitis. Sienna also gains CT340 (SNA-125...
...Creabilis plc , Canterbury, U.K. Sienna Biopharmaceuticals Inc. , Westlake Village, Calif. Business: Autoimmune, dermatology Chris Lieu CT327 CT340 Creabilis Sienna...